Technical Analysis for SABS - SAB Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Support | Bullish | 1.95% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.95% | |
| Wide Bands | Range Expansion | 1.95% | |
| Gapped Up | Strength | 1.95% | |
| Oversold Stochastic | Weakness | 1.95% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 14 hours ago |
| Down 2 % | about 18 hours ago |
| Gap Up Closed | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Down 1% | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
SAB Biotherapeutics, Inc. Description
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Infectious Diseases Diabetes Autoimmune Disease Antibodies Antibody Immunotherapies Influenza Us Government Genetic Engineering Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.721 |
| 52 Week Low | 2.16 |
| Average Volume | 92,124 |
| 200-Day Moving Average | 3.50 |
| 50-Day Moving Average | 2.98 |
| 20-Day Moving Average | 3.37 |
| 10-Day Moving Average | 3.24 |
| Average True Range | 0.37 |
| RSI (14) | 48.72 |
| ADX | 20.89 |
| +DI | 16.14 |
| -DI | 14.82 |
| Chandelier Exit (Long, 3 ATRs) | 3.25 |
| Chandelier Exit (Short, 3 ATRs) | 3.72 |
| Upper Bollinger Bands | 4.10 |
| Lower Bollinger Band | 2.63 |
| Percent B (%b) | 0.34 |
| BandWidth | 43.61 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.11 |
| MACD Histogram | -0.0699 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.46 | ||||
| Resistance 3 (R3) | 3.45 | 3.34 | 3.41 | ||
| Resistance 2 (R2) | 3.34 | 3.25 | 3.34 | 3.39 | |
| Resistance 1 (R1) | 3.23 | 3.20 | 3.18 | 3.24 | 3.37 |
| Pivot Point | 3.12 | 3.12 | 3.09 | 3.12 | 3.12 |
| Support 1 (S1) | 3.01 | 3.03 | 2.96 | 3.02 | 2.89 |
| Support 2 (S2) | 2.90 | 2.98 | 2.90 | 2.87 | |
| Support 3 (S3) | 2.79 | 2.90 | 2.86 | ||
| Support 4 (S4) | 2.80 |
